Brain Peptide TLQP-62 Prevents Inflammation-Induced Memory Loss, Depression, and Anxiety in Mice | Research

The takeaway

The neuropeptide TLQP-62 prevented inflammation-induced memory deficits, depression, and anxiety in mice by activating BDNF/TrkB signaling and reducing brain inflammation.

Triple protection: memory + mood + anxiety
A single pretreatment with TLQP-62 prevented inflammation-induced deficits across all three behavioral domains, with all effects dependent on BDNF signaling

What the researchers found

The neuropeptide fragment TLQP-62 (derived from the VGF protein) prevented inflammation-induced memory deficits, depression-like behavior, and anxiety-like behavior in mice when injected into the brain before an inflammatory challenge (LPS). TLQP-62 also reduced neuroinflammation and oxidative stress markers. Critically, when BDNF expression was knocked down using a viral vector, TLQP-62's protective effects were blocked — demonstrating that the peptide works through the BDNF/TrkB signaling pathway.

Why it matters

Neuroinflammation is increasingly recognized as a driver of depression, anxiety, and cognitive decline. This study identifies a specific neuropeptide (TLQP-62) that can protect against inflammation-induced brain dysfunction through BDNF signaling — a pathway already known to be central to antidepressant action. It suggests peptide-based approaches could offer a new therapeutic angle for neuropsychiatric conditions linked to inflammation.

The numbers in context

TLQP-62: 2 μg/side i.c.v. · LPS: 0.5 mg/kg i.p. · Prevented recognition memory deficits · Prevented depression-like behavior · Prevented anxiety-like behavior · Effects blocked by BDNF knockdown

How the study worked

ICR mice received intracerebroventricular injection of TLQP-62 (2 μg/side) 1 hour before intraperitoneal LPS (0.5 mg/kg) to model inflammation-induced neuropsychiatric dysfunction. Behavioral tests included novel object recognition (memory), forced swim test and sucrose preference test (depression), and elevated zero maze (anxiety). Neuroinflammation and oxidative stress markers were measured. BDNF-shRNA lentivirus was used to knock down BDNF and test whether TLQP-62's effects depended on BDNF/TrkB signaling.

Who was studied

Male ICR mice with LPS-induced neuroinflammation

What this study cannot tell us

Mouse study with invasive brain injection — not translatable to practical therapy. Single pretreatment design does not show whether the peptide works after inflammation has already started. The LPS model is a simplified acute inflammation model that may not replicate chronic neuroinflammatory conditions. TLQP-62 cannot cross the blood-brain barrier in its current form.

How to read the evidence

This is an early-stage animal study using invasive brain injection in a mouse model of acute inflammation. While the mechanistic evidence (BDNF knockdown experiment) is well-designed, the findings are far from clinical translation due to the delivery method and simplified disease model.

When this study was published

Published in 2017, this study established the anti-neuroinflammatory potential of TLQP-62. Research on VGF-derived peptides has continued, though no clinical applications have emerged from this line of work yet.

The bigger picture

The connection between inflammation and mental health is one of the most active areas of psychiatry research. Many patients with depression show elevated inflammatory markers, and traditional antidepressants don't work well for inflammation-driven depression. TLQP-62 represents a peptide-based approach that directly targets the BDNF pathway — the same pathway that existing antidepressants indirectly activate — but through a mechanism that also addresses neuroinflammation and oxidative stress.

Questions still open

Can TLQP-62 or analogs be modified to cross the blood-brain barrier, enabling non-invasive delivery for potential clinical use?
Does TLQP-62 work when administered after inflammation has already established, or only as a preventive treatment?
Could TLQP-62 enhance the effects of existing antidepressants in patients with inflammation-associated treatment-resistant depression?

Common questions

What is TLQP-62 and where does it come from?

TLQP-62 is a 62-amino-acid peptide fragment derived from the VGF nerve growth factor protein. VGF is produced in neurons and is involved in energy balance, mood regulation, and memory. TLQP-62 is its C-terminal (end) fragment, named after its first four amino acids (T-L-Q-P).

Could this peptide be developed into an antidepressant?

It's too early to say. TLQP-62 works in mice when injected directly into the brain, but it can't cross the blood-brain barrier on its own. Researchers would need to develop modified versions that can reach the brain through practical routes (like injection or nasal delivery) before it could be considered as a therapeutic option.

Read the original research

Neuropeptide VGF C-Terminal Peptide TLQP-62 Alleviates Lipopolysaccharide-Induced Memory Deficits and Anxiety-like and Depression-like Behaviors in Mice: The Role of BDNF/TrkB Signaling.

ACS chemical neuroscience, 8(9), 2005-2018

View on PubMed ↗Publisher’s paper ↗

Citation

Li, Chenli; Li, Mengmeng; Yu, Hanjie; Shen, Xinbei; Wang, Jinting; Sun, Xin; Wang, Qinwen; Wang, Chuang. (2017). Neuropeptide VGF C-Terminal Peptide TLQP-62 Alleviates Lipopolysaccharide-Induced Memory Deficits and Anxiety-like and Depression-like Behaviors in Mice: The Role of BDNF/TrkB Signaling.. ACS chemical neuroscience, 8(9), 2005-2018. https://doi.org/10.1021/acschemneuro.7b00154